Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion type Assertion NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_head.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion evidence source_evidence_literature NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion SIO_000772 16210092 NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion wasDerivedFrom befree-20140225 NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.
- NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion wasGeneratedBy ECO_0000203 NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.